Date: 07th August, 2026
KMP / Board / Auditor Changes
Not Specified
Dividend Declaration or Non-Declaration
Not Specified
Board Meeting Outcomes
Not Specified
Financial Results (Standalone & Consolidated)
Not Specified
Auditor’s Report
Not Specified
Disinvestment / Strategic Actions
Not Specified
Other Operational / Legal / Strategic Disclosures
This is a compliance disclosure submitted to the National Stock Exchange of India Limited.
The company is fulfilling its regulatory obligation under SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/ I/3750/2026 dated 30th January, 2026.
The disclosure encloses a report from the company's Registrar and Share Transfer Agent (RTA), M/s. Aarthi Consultants Private Limited, for the period ended July 2026.
The report details the status of requests received from shareholders for the re-lodgement of transfer requests for physical shares under a special window provided by the SEBI circular.
RTA Report Details (Period: July 2026):
- Number of requests received during the month: NIL
- Number of requests processed during the month: NIL
- Number of requests approved during the month: NIL
- Number of requests rejected during the month: NIL
- Average time taken for processing of requests: NA
The report was signed by Jagan Mohan Gobburi, Compliance Officer at Aarthi Consultants Pvt Ltd, on 05/08/2026.
The company confirmed the report is also available on its website at www.balaxipharma.in.
The letter to the exchange was digitally signed by Aman Purohit (Company Secretary & Compliance Officer, ICSI Membership No.: A59345) on behalf of Balaxi Pharmaceuticals Limited.